On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...

Good day, everyone, and welcome to today's Neurocrine Biosciences reports Q4 and fiscal year 2024 Earnings Call. (Operator Instructions) Please note today's call will be recorded and I will be ...

Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $148.00. The company’s shares closed yesterday at $150.51.

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate. Analysts ...

Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently sold 1,207 shares of the company's common stock. The shares were sold at an average price of $152. ...

Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The business has a 50-day moving average of $138.41 and a 200-day moving average of $131.64.

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza revenue guidance for around 10% year-over-year growth ...